Wyniki wyszukiwania

1

Can arginase be a marker of the large bowel neoplasia?

100%

Konarska L., Kolasa T., Albrecht P., Regula A.

Acta Biochimica Polonica

|

1993

|

tom 40

|

nr 1

2

Trends in antimicrobial susceptibility of Campylobacter isolates in Poland [2000-2007]

64%

Rozynek E., Dzierzanowska-Fangrat K., Szczepanska B., Wardak S., Szych J., Konieczny P., Albrecht P., Dzierzanowska D.

Polish Journal of Microbiology

|

2009

|

tom 58

|

nr 2

111-115

This study analysed the pattern of antibiotic resistance in 251 Campylobacter strains isolated from symptomatic children hospitalized in 4 large paediatric hospitals in Poland from 2000 through 2007. The highest resistance was found for ciprofloxacin (49.5% for C. jejuni and 51.3% for C. coli), followed by tetracycline (17.5% and 18.0%, respectively), and ampicillin (13.2% and 10.2%, respectively). Almost all isolates were susceptible to macrolides. As much as 22.6% of C. jejuni and 25.6% of C. coli were resistant to more than one class of antimicrobial agents. Multidrug resistance (defined as resistance to at least two classes of antimicrobials) rose significantly from 5.1% in 2000-2003 to 34.6% in 2004-2007.

3

Artykuł dostępny w postaci pełnego tekstu - kliknij by otworzyć plik

Faecal Microbiota Transfer - a new concept for treating cytomegalovirus colitis in children with ulcerative colitis

64%

Karolewska-Bochenek K., Lazowska-Przeorek I., Grzesiowski P., Dziekiewicz M., Dembinski L., Albrecht P., Radzikowski A., Banaszkiewicz A.

Annals of Agricultural and Environmental Medicine

|

2021

|

tom 28

|

nr 1

4

Serotype-specific pneumococcal status prior to PCV 13 administration in children and adolescents with inflammatory bowel disease

52%

Banaszkiewicz A., Targonska B., Kowalska-Duplaga K., Karolewska-Bochenek K., Sieczkowska A., Gawronska A., Grzybowska-Chlebowczyk U., Krzesiek E., Lazowska-Przeorek I., Kotowska M., Sienkiewicz E., Walkowiak J., Gregorek H., Radzikowski A., Albrecht P.

Polish Journal of Microbiology

|

2016

|

tom 65

|

nr 1

The aim of this study was to evaluate the serotype-specific pneumococcal status of children and adolescents with inflammatory bowel disease (IBD) who were naïve to pneumococcal vaccination before administering the 13-valent pneumococcal conjugate vaccine (PCV 13). This was an open, prospective study on children and adolescents aged 5–18 years who had IBD and were naïve to pneumococcal vaccination. A single dose of PCV 13 was administered to each patient. The geometric mean concentrations (GMCs) were measured for all 13 serotypes. A total of 122 subjects completed the study. Prevaccination GMCs ranged from 0.55 μg/ml (serotype 4) to 4.26 μg/ml (serotype 19A). Prior to the administration of PCV 13, high GMCs were detected in older children and adolescents who had IBD and were naïve to pneumococcal vaccination.

Ograniczanie wyników

Can arginase be a marker of the large bowel neoplasia?

Trends in antimicrobial susceptibility of Campylobacter isolates in Poland [2000-2007]

Faecal Microbiota Transfer - a new concept for treating cytomegalovirus colitis in children with ulcerative colitis

Serotype-specific pneumococcal status prior to PCV 13 administration in children and adolescents with inflammatory bowel disease